|Bid||170.48 x 2200|
|Ask||172.49 x 1800|
|Day's Range||172.80 - 172.80|
|52 Week Range||151.40 - 234.00|
|Beta (3Y Monthly)||0.67|
|PE Ratio (TTM)||10.89|
|Forward Dividend & Yield||2.68 (1.55%)|
|1y Target Est||N/A|
Corona beer maker Constellation Brands Inc is in advanced talks to sell some of its low-end wines to privately held E.&J. Gallo Winery, CNBC reported on Friday, citing people familiar with the situation. In early February, Constellations said it was looking to sell some of its lower-end wine brands, as it doubles down on more profitable high-end segment and shift towards beer and cannabis products that target a younger demographic. Constellation said it doesn't respond to rumors or speculations.
Constellation Brands is in advanced talks to sell its some of its low-end wine brands to E. & J. Gallo Winery, people familiar with the situation tell CNBC. Constellation put its U.S. wine business, which includes brands like Clos du Bois, Mark West and Arbor Mist, up for sale last year as part of its move into cannabis. Sales of non-premium wine have slowed, as millennials focus increasingly on health and alternative indulgences like cannabis.
CHICAGO, March 14, 2019 -- Modelo, the beer brewed for those with The Fighting Spirit™, announces its newest ready-to-drink chelada, Modelo Chelada Limón y Sal. The newest.
Constellation Brands Inc NYSE:STZView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for STZ with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold STZ had net inflows of $4.76 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is strong relative to the trend shown over the past year. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. STZ credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
It has built one of the most diverse and far-reaching businesses in the legal marijuana space, but there are some missing pieces in its puzzle.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / There are three main kinds of marijuana stocks: 1. Marijuana producers who cultivate marijuana, produce cannabis products, and distribute the products to customers. ...
VICTOR, N.Y., March 07, 2019 -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today it will report financial results for its.
Constellation Brands stock can rise by a third, an analyst said—and that’s not even counting the company’s stake in Canadian cannabis producer Canopy Growth.
Linton recalled a story where he received an e-mail more than three years ago from rapper Snoop Dogg and the two initially collaborated on a line of marijuana products. At the same time, Snoop co-hosted a variety show with Stewart and an introduction was made. Stewart eventually agreed to take an advisory role at Canopy Growth.
[Editor's note: This story was originally published in December 2018. It has since been updated and republished, but the author's position may have shifted since its last publication.]Any cursory look at the markets would reveal that 2018 wasn't the best year for investors. That goes for speculative assets as well, including marijuana stocks. Although going green has proven net positive for the early birds, the sector tanked heavily during the October selloff. Still, I wouldn't drop them from your list of stocks to buy just yet.Despite their well-publicized fall from grace, several marijuana stocks have stabilized from their severe correction. While that's no guarantee that the industry is done spilling blood, the deflated prices will almost certainly attract speculators. Should enough risk-takers enter the arena, publicly traded cannabis companies will jump higher, even if it's only a temporary swing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, some other factors suggest that marijuana stocks may enjoy a sustained rise. First, none of the big waves currently spooking benchmark indices affect the legal cannabis industry. Whether it's political unrest in the Middle East, the spiraling protests in Paris or the ugly Huawei controversy, marijuana, for now, is mostly a North American issue.Second, medical cannabis, on the one hand, potentially offers significant social utility. A stunning Bloomberg article analyzed whether Gilead Sciences (NASDAQ:GILD) made the right business decision in producing a drug that cured diseases rather than managing them. The perception exists that big pharma companies should focus primarily focus on revenue generation rather than medical breakthroughs.On the other hand, medical marijuana companies have no such quandaries. Because they are typically much smaller outfits, they don't mind the inability to patent a naturally occurring plant. If anything, an organization that produces a proven, effective cannabis strain would represent a buyout target. This asymmetry challenges Big Pharma, but makes marijuana-based pharmaceuticals among the best stocks to buy. * 9 Trade War Stocks to Sell on U.S.-China Deal News While the sector remains risky, the deflated market environment offers attractive deals on these 10 marijuana stocks. Tilray (TLRY)Tilray (NASDAQ:TLRY) easily represents the most interesting and controversial picks among marijuana stocks to buy for next year. Within a few months after its initial public offering, TLRY stock pulled a ten-bagger. But as you know, the victory was short-lived, and Tilray came crashing down to earth.Naturally, several analysts and commentators blasted the company as an unsustainable bubble. Keep in mind, though, that since its IPO, TLRY stock is up over 470%. I wouldn't dismiss such a performance as a failure. Moreover, shares have stabilized near the $100 level. If this company was as terrible as the bears claimed, I doubt TLRY would ride this support line.Now, it's easy to dismiss any individual opinion. It's much harder when a banking giant like Barclays (NYSE:BCS) increases their position. Clearly, they view TLRY as one of the best stocks to buy in 2019, and they're putting their money where their mouth is. Canopy Growth (CGC)The prior two months have not been for Canopy Growth (NYSE:CGC). Taking a similar route to most other marijuana stocks, CGC dropped 26% in October. The following November appeared promising, building off a sharp burst of momentum. Unfortunately, the rally lost traction and CGC ended up losing double-digits for the month.But what I like about Canopy Growth is that true to its name, it's a steady grower. Despite the recent sharp losses, its longer-term bullish trend channel remains intact. I wouldn't consider hitting the panic button unless shares started to decisively fall below the $25 level. That said, I think the broader fundamentals favor CGC stock. * 10 High-Yield Monthly Dividend Stocks Tilray has a financial institution backing it. For Canopy Growth, they have alcoholic-beverages maker Constellation Brands (NYSE:STZ). This is a trend that investors, even the skeptical ones, shouldn't ignore. Big money is increasingly stepping into the cannabis sector, making CGC one of the best stocks to buy despite its well-publicized setbacks. Cronos Group (CRON)While most marijuana stocks have struggled to rekindle their prior catalysts, Cronos Group (NASDAQ:CRON) currently stands above the competition. For the month so far, CRON stock has streaked to an amazing 39% lead. Of course, most of that optimism comes courtesy of Altria Group (NYSE:MO).The iconic tobacco company made headlines when it announced a partnership with Cronos. The deal, worth $1.8 billion, provides CRON with a boatload of cash to further develop its cannabinoid (CBD) products. On the other side of the fence, Altria needs something fresh to reinvigorate its traditional tobacco business.A key long-term synergy could be the vaporizer market. Vaping CBD e-liquids have taken off in terms of popularity. Altria has attempted to break into the vaporizer market with its own heat-not-burn tobacco products. But with Cronos' expertise in CBD, Altria has another angle in this sector to work.In the meantime, feel free to put CRON in your list of best stocks to buy for next year. Aurora Cannabis (ACB)Aurora Cannabis (NYSE:ACB) has suffered a disjointed long-term performance in the markets, even compared to other marijuana stocks. In 2017, ACB stock shot from near-obscurity to the toast of Wall Street. This year, ACB has shown flashes of brilliance, but little to show for it overall.I expect the cannabis sector to wake from its slumber. When it does, the currently embattled ACB has the potential to become one of the best stocks to buy for 2019. The markets really haven't responded positively to Aurora's buyout of Farmacias Magistrales. Farmacias made news when it became the first, and so far only Mexican importer of raw materials that contain the psychoactive component THC. * 7 Dividend Stocks Already Rewarding Shareholders In 2019 The buyout allows Aurora a viable channel to Latin America's medical-marijuana market. In addition to Farmacias, ACB has operations in Colombia and Uruguay. Should the industry establish medical breakthroughs in Latin America, advocates will pressure the U.S. to further loosen federal cannabis restrictions. Auxly Cannabis (CBWTF)One of the most common misconceptions is that legal-cannabis advocates are only "fronting" to get high. While that use is unavoidable, the botanical industry has several legitimate applications. On the business aspect, several investors assume that all cannabis companies focus on growing weed.But as Auxly Cannabis (OTCMKTS:CBWTF) demonstrates, marijuana stocks feature the same vibrancy and dynamism as other commodity related investments. Auxly specializes in all areas of the legal-cannabis supply chain, with a primary focus on upstream operations. This involves partnering with companies that grow the actual product.In addition, CBWTF levers a viable midstream operation. This includes activities such as extraction, processing and branding. It also involves longer-term efforts like research and development.The biggest advantage for CBWTF to pull this streaming business off is its balance sheet. With a favorable cash-to-debt ratio, Auxly can make key acquisitions and investments while the cannabis market is still young. Origin House (ORHOF)Formerly known as CannaRoyalty, Origin House (OTCMKTS:ORHOF) is another cannabis firm that made its name through streaming businesses. And while it still generates some revenue through its initial line of work, ORHOF has become a powerhouse in branding.The proof is in its utter domination of California. Unbeknownst to me prior to this write-up, the Golden State is the world's largest legal cannabis market. With a title like that, it's a wonder how anything gets done around here. Joking aside, Origin House boasts more than 450 California-based dispensaries and more than 50 popular brands. * 7 Emerging Market Stocks to Buy on This Dip In other words, if you can make it in California, you can make it anywhere. This bodes very well for ORHOF stock. Last month's midterm elections proved that legal weed is gaining serious momentum. Inevitably, more recreational markets will open, allowing Origin House to expand its dominating presence. Marimed (MRMD)Let's face facts: Marijuana stocks don't exactly have the greatest reputation for stability. That goes five-fold for over-the-counter offerings. One notable exception to this rule is Marimed (OTCMKTS:MRMD).While other sector players hemorrhaged severely during the October rout, MRMD stock actually enjoyed a standout performance, gaining nearly 19%. That said, Marimed eventually gave up those gains and then some. Since the first of November, MRMD is down a little over 17%.Still, I think it's fair to say that compared against other marijuana stocks to buy, Marimed has held up well. Heading into the new year, MRMD has the potential to turn heads.Its biggest advantage is its highly demanded consultation services. Covering everything from licensing application support to facilities management, MRMD provides relevant and critical insights for budding entrepreneurs. Plus in my opinion, Marimed levers one of the brightest and well-rounded leadership teams in the marijuana industry. Medmen Enterprises (MMNFF)Marijuana retail outfit Medmen Enterprises (OTCMKTS:MMNFF) suddenly became one of the best stocks to buy in botany around mid-October. Within a matter of days, MMNFF stock skyrocketed over 60%. But like most over-the-counter affairs, Medmen gave up its profits just as quickly.Since its peak closing price, MMNFF stock has dropped a humbling 53%. I get that most investors will balk at such volatility. However, for the speculator, I sense serious growth opportunities for Medmen.The company has established itself as a retailer of premium cannabis products. Yet many investors may not appreciate that Medmen is a vertically integrated organization. From its upstream production operation down to extraction, branding and distribution, Medmen essentially controls its supply chain. This is a "farm-to-bong" business at its finest. * 5 Cheap ETFs Worth Considering As Medmen CEO Adam Bierman stated recently, this structure affords the company generous margin-expansion possibilities. Further, the aforementioned high-profile deals only help validate smaller players like MMNFF stock. Aleafia Health (ALEAF)Broader and sector weakness has hurt virtually all marijuana stocks. However, the lesser-known names have experienced disproportionate pain. Unfortunately, this is something that Canadian cannabis firm Aleafia Health (OTCMKTS:ALEAF) knows all too well.But despite its severe market loss over the past two-and-a-half months, ALEAF stock offers a speculative opportunity for risk-takers. For starters, the underlying company features the largest network of referral-only medical cannabis clinics in Canada. Furthermore, their patient base continues to increase as the industry gains social recognition and acceptance.Management has also invested heavily in cultivation facilities, targeting an annual growing capacity of 98,000 kilograms in 2019. Most importantly, Aleafia has the substance to back up the outlook. In its most recent third-quarter earnings report, the company increased revenue 36% year-over-year. Diego Pellicer Worldwide (DPWW)We've arrived at the end of our journey regarding marijuana stocks to buy in 2019. In keeping with my loose tradition, I like to throw in an extremely speculative name. And don't roll your eyes at me: you know you want to know!The following idea comes from an InvestorPlace reader named Anthony. He asked my opinion regarding Diego Pellicer Worldwide (OTCMKTS:DPWW). My answer to him is the same one I'm giving to you, which is that DPWW stock is extremely risky. Aside from its distressingly low trading volume and market capitalization, Diego Pellicer lacks financial strength to convincingly pull off its licensing and royalties business model.However, I'm intrigued with its premium branding business. Not that I would know, but Diego Pellicer specializes in high-class cannabis products. As companies like Origin House and Medmen have proven, cannabis users eschew quantity for quality. That could lead to a surprising turnaround for DPWW stock. * 3 Market-Leading Stocks to Buy With Red on the Street Or you can lose every cent that you put in.As of this writing, Josh Enomoto is long MRMD and ALEAF. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Should Be Worried About a Data Dividend * 5 Cheap ETFs Worth Considering * 7 Cheap Stocks Under $5 That Could Soar Compare Brokers The post 10 Top Pot Stocks 2019 Has to Offer appeared first on InvestorPlace.
A recent report by Zenith Global, a leading global food and drink consulting firm, projects that the US market for cannabis infused drinks will grow to $1.4 Billion by 2024, an almost fifteen times (15x) increase from 2018 sales of just $89million. New Age Beverage (NBEV), the US based energy and natural beverage manufacturer announced in the fall of 2018 that it was beginning to produce CBD infused beverages. At the end of 2018, NBEV launched its Noni+Collagen product, and announced that within its first two months of sales, generated over $4 million in revenue in its first two months in initial test markets.
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Canada’s cannabis landscape is evolving rapidly. In order to get a better understanding of how the marijuana industry is progressing, we have identified 5 emerging marijuana industry leaders in categories such as retail, cultivation, extraction, overall size, and international footprint. Westleaf Inc. (WL.V) (WSLFF), a vertically integrated cannabis company focused on innovative retail experiences and engaging cannabis brands as well as cultivation, production and extraction of cannabis products, recently announced the opening of a Prairie Records cannabis retail store in Warman, Saskatchewan.
Anheuser-Busch InBev, Molson Coors Brewing, Heineken and Constellation Brands had been discussing teaming up for a national ad campaign to revive lagging U.S. beer sales. AB InBev's Super Bowl ad for Bud Light targeted two of Molson Coors' beers for using corn syrup.
A fight between America’s two biggest brewers is jeopardizing a proposed “Got Milk?”-style campaign intended to help struggling beer makers win back drinkers who have defected to wine and spirits. Anheuser-Busch InBev SA, Molson Coors Brewing Co., Heineken NV and Constellation Brands Inc. have for over a year discussed a potential multimillion-dollar, brand-agnostic campaign aimed at improving the overall health of the beer category. The rift began when AB InBev ran three Super Bowl TV ads earlier this month highlighting MillerCoors’s use of corn syrup in Coors Light and Miller Lite.